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Abstract
Background: The effect of rotavirus in developed countries is mainly economic. This study aimed to assess the
indirect costs induced by rotavirus acute gastroenteritis (RVAGE) in Spain.
Methods: A prospective observational study was conducted from October 2008 to June 2009. It included 682
children up to 5 years of age with acute gastroenteritis (AGE) who attended primary care (n = 18) and emergency
room/hospital settings (n = 10), covering the regions of Galicia and Asturias (North-west Spain). All non-medical
expenses incurred throughout the episode were recorded in detail using personal interviews and telephone
contact.
Results: Among the 682 enrolled children, 207 (30.4%) were rotavirus positive and 170 (25%) had received at least
one dose of rotavirus vaccine. The mean (standard deviation) indirect cost caused by an episode of AGE was
estimated at 135.17 (182.70) Euros. Costs were 1.74-fold higher when AGE was caused by rotavirus compared with
other etiologies: 192.7 (219.8) Euros vs. 111.6 (163.5) Euros (p < .001). The costs for absenteeism were the most
substantial with a mean of 91.41 (134.76) Euros per family, resulting in a loss of 2.45 (3.17) days of work. In RVAGE
patients, the absenteeism cost was 120.4 (154) Euros compared with 75.8 (123) for the other etiologies (p = .002),
because of loss of 3.5 (3.6) vs 1.9 (2.9) days of work (p < .001). Meals costs were 2-fold-higher (48.5 (55) vs 24.3 (46)
Euros, p < .001) and travel costs were 2.6-fold-higher (32 (92) vs 12.5 (21.1) Euros, p = .005) in RVAGE patients
compared with those with other etiologies. There were no differences between RVAGE and other etiologies groups
regarding costs of hiring of caregivers or purchase of material. Patients with RVAGE were admitted to hospital
more frequently than those with other etiologies (47.8% vs 14%, p < .001).
Conclusions: Rotavirus generates a significant indirect economic burden. Our data should be considered in the
decision-making process of the eventual inclusion of rotavirus vaccine in the national immunization schedule of
well developed countries.
Background
Rotavirus is the leading cause of acute gastroenteritis
(AGE) in infants and children under 5 years of age,
causing 600,000 deaths worldwide [1]. In developed
countries, death by rotavirus is very rare, but infection
by rotavirus is an important cause of morbidity, and it
represents a high cost. At the age of 5 years, almost all
children will have suffered an episode of acute rotavirus
gastroenteritis (RVAGE), 1 of each 5 will need a visit to
the physician, 1 of 65 will be hospitalized and approxi-
mately 1 of 293 will die [1-5]. In the last 20 years, the
mortality rates by rotavirus have decreased in the more
developed countries, but improvement in hygienic-
healthy conditions has not modified the global incidence
of the disease, and therefore, vaccination is the most
efficacious measure to prevent this illness [6-9].
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In the USA, it has been estimated that rotavirus infec-
tions generate direct sanitary costs of 250 million of dol-
lars per year and the indirect costs are more than a
billion dollars. Despite the fact that rotavirus gastroen-
teritis is currently considered to be the most common
pediatric disease in the European Community preventa-
ble by vaccination, specific data about the indirect eco-
nomic burden generated by rotavirus in Europe is
limited [7,10-15]. In Spain, economic data on rotavirus
are even more scarce, and its impact in terms of indirect
costs is almost unknown [6,16-20]. The REVEAL study
considered both direct and indirect costs, and compiled
data from 7 countries including Spain [20]. Another sin-
gle centre hospital-based study performed by our group
showed that the indirect costs generated by RVAGE
were 2.6-fold higher than those induced by other etiolo-
gies [18,19].
The aim of the ROTACOST study was to prospectively
determine the indirect economic burden of AGE caused
by rotavirus in a broad population including not only hos-
pital-care but also emergency and primary care settings.
Methods
A prospective, observational multicentric study was con-
ducted from October 2008 to June 2009 using a pedia-
tric research network (ROTACOST study group
-ReGALIP - http://www.regalip.org) that included pri-
mary, emergency and hospital care settings. Any patient
up to 5 years old seeking care because of an AGE epi-
sode was considered eligible for the study if they fulfilled
the following conditions: a) 3 or more bowel motions
less consistent than usual, associated or not associated
with vomiting, in a 24-hour period; b) symptoms must
have occurred within 7 days of enrollment, preceded by
a 14-day symptom-free period; and c) an episode of
AGE must not have occurred in the 2 weeks prior to
the onset of current symptoms. All nonmedical expenses
from the start to the end of the diseases were recorded
in detail using personal interviews and telephone con-
tact. A fecal immunoassay for rotavirus detection in a
fecal sample was performed in all included patients
(VIKIA Rota-Adeno®, Biomerieux). This study was
approved by the reference ethics committee, Comité
Etico de Investigación de Galicia (ref 2009/039). All par-
ents or guardians received information about the study
and signed an informed consent before study entry.
Data collection
Clinical, epidemiological and economic data were
recorded and uploaded through a specific web site. The
data collection was performed in 2 phases: first, person-
ally during a contact visit; and second, by either phone
or a planned visit once the acute episode had finished.
During the first contact, the parents received specific
information and guidance for data collection until the
second survey/visit.
Methods to estimate indirect expenses
All expenses incurred before, during, and after patient
contact and study entry, from the start of symptoms to
total recovery of the child, were recorded. Expenses dur-
ing care or hospitalization for patient diets, materials, or
medication were considered as part of direct (hospital)
costs, and were not counted as indirect expenses. Prior-
ity was always given to the exact cost, when known by
the parents. Costs in the following areas were evaluated
and calculated as specified:
1. Work
Estimated cost of work lost was calculated by the
following order: (a) using the exact amount, if
the person interviewed knew the exact rate per
hour, (b) based on the annual/monthly/weekly
earnings, the mean amount earned per hour,
considering the numbers of hours worked per
week, and the number of hours lost, and (c)
based on the Spanish minimum mandatory salary
for the year 2008 (Royal Decree 1763/2007), i.e.,
28.42 Euros per day. Both spouses were consid-
ered if they both worked.
2. Travel
Any journey to the physician’s office, hospital,
pharmacy, or related to or caused by the child’s
condition was considered. Distance traveled was
registered, and the cost of traveling by car was
calculated by applying article 8.A.2 of the Regula-
tions of the Personal Income Tax, approved by
the Royal Decree 1775/2004, which sets a cost of
0.19 Euros per kilometer traveled.
3. Caregiver
This included day nursery or caregiver expenses,
but only when contracted for care of the other
siblings.
4. Meals
Expenses incurred by meals outside the home
because of the disease of the child. The number
of meals and the cost per meal were recorded.
5. Material
This included any expenses derived from the
purchase of oral rehydration or similar solutions,
antidiarrheal agents or other drugs prescribed by
the physician, additional number of diapers used
and their cost, specific special diets (e.g., lactose-
free), topical creams, or any other materials pur-
chased during the time of the disease that were
adequately explained by the parent or guardian.
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Statistical analysis
When appropriate, data are presented as mean (standard
deviation). Patients were divided into “rotavirus acute
gastroenteritis” (RVAGE) and “other etiologies” groups
for comparison purposes. Normal distribution of the
data was assessed with the Kolmogorov-Smirnov test,
and the Mann-Whitney or Student’s t test was used
accordingly. Multiple linear regression analysis was per-
formed to adjust for the effect of the etiology (rotavirus
vs another etiology), admission, age and sex of patients
in the generated costs. A value of p < 0.05 was consid-
ered significant. Statistical analyses were performed
using SPSS version 17.0 (SPSS Inc., Chicago Illinois,
USA).
Results
A total of 765 children were invited to participate in the
study. Fifteen children declined to participate, 56 did
not complete the study and 12 were withdrawn because
of missing data in any of the study end-points. Finally,
682 patients suffering from AGE with a mean age of
18.5 (12.9) months were included (Table 1). A total of
207 (30.4%) children were positive for rotavirus and 170
(25%) had received at least 1 dose of rotavirus vaccine.
Each child required a mean of 2.1 (1.2) medical visits
during the disease, and 163 (23.9%) patients required
hospital admission, with a mean stay of 4.4 (2.1) days.
Patients with RVAGE were admitted to hospital more
frequently than patients with other etiologies (47.8% vs
14.0%, p < 0.001) (Table 1).
The mean indirect costs caused by an episode of AGE
was estimated at 135.17 (182.7) Euros. Costs were 1.74-
fold higher when AGE was caused by rotavirus compared
with other etiologies (192.7 [219.8] Euros vs 111.6 [163.5]
Euros, p = 0.001) (Table 2). Costs derived from absentee-
ism were the more substantial (64.5% of total costs), with
a mean of 91.41 (134.76) Euros per family, resulting from
the loss of 2.45 (3.11) days of work. In RVAGE patients,
the absenteeism cost was 120.4 (154) Euros compared
with 75.8 (123) Euros for those with other etiologies (p =
.002), because of the loss of 3.5 (3.6) vs 1.9 (2.9) days of
work (p < .001). Costs from purchase of materials were
estimated at 34.4 (51.35) Euros per family, and repre-
sented 25.4% of overall costs. The remaining 36.9% of
indirect costs were generated by the following: 5.5 (7.5)
meals outside the home with a cost of 33.3 (51.4) Euros;
hiring of specific caregivers with a cost of 14.7 (41.40)
Euros; and traveling expenditure of 18.6 (55) Euros for a
mean of 56.1 km (113.5) in each case. Meals costs were
2-fold-higher in RVAGE compared with those in other
etiologies (48.5 [55] Euros vs 24.3 [46] Euros, p < .001).
Travel costs were 2.6-fold-higher in RVAGE compared
with those in other etiologies (32 [92] Euros vs 12.5
[21.1] Euros, p = .005). There were no differences
between groups regarding costs of hiring of caregivers or
purchase of material (Table 2).
Indirect costs were also significantly higher in hospita-
lized patients compared with those in non-hospitalized
patients (293.4 [261.2] Euros vs 85.5 [110.4] Euros, p <
.001).
Discussion
The ROTACOST study showed that there is an out-
standing burden generated by AGE in the North-west of
Table 1 Summary of patient characteristics
GLOBAL (All
etiologies)
(n = 682)
Gastroenteritis by
rotavirus
(n = 207)
Gastroenteritis by other
etiologies
(n = 428)
P
Age (months) 0.563
0-6 months 111 (16.3%) 28 (13.5%) 75 (17.5%)
7-12 months 141(20.7%) 42 (20.3%) 89 (20.8%)
13-24 months 253 (37.1%) 81 (39.1%) 152 (35.5%)
25-36 months 109 (16.0%) 38 (18.4%) 67 (15.7%)
37-60 months 68 (10.0%) 18 (8.7%) 45 (10.5%)
Sex (male %) 383 (56.2%) 116 (56.0%) 241 (56.3%) 0.949
Rotavirus vaccination (complete or partial
vaccination)
178 (26.1%) 11 (5.3%) 159 (37.1%) <
0.001
Maximum number of depositions in 24 hours 6.9 ± 3.4 (6.0) 8.0 ± 4.0 (7.0) 6.3 ± 3.0 (6.0) <
0.001
Number of times needed medical care 2.1 ± 1.2 (2.0) 2.3 ± 1.3 (2.0) 2.0 ± 1.2 (2.0) <
0.001
Gastroenteritis episode duration (days) 7.3 ± 3.5 (7.0) 7.6 ± 2.9 (7.0) 7.2 ± 3.7 (6.0) 0.132
Hospital admission 163 (23.9%) 99 (47.8%) 60 (14.0%) <
0.001
Length of hospital stay (days) 4.4 ± 2.1 (4.0) 4.5 ± 2.1 (4.0) 4.4 ± 2.1 (4.0) 0.850
“Global” represents all patients included in the study. P values are provided for comparison between rotavirus and other etiologies subgroups.
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Spain in terms of indirect costs, mainly because of the
absenteeism of parents. When rotavirus is the etiological
agent, costs are 75% higher compared with those for
other etiologies, and these costs account for one third of
the Spanish minimum official salary.
Few previous studies in this setting were prospective,
focused on indirect costs and included all types of
patients from primary care to hospital care [18-21].
Only Lee et al. have compiled such a comprehensive
collection of indirect costs in the USA setting [21]. The
REVEAL study assessed both the direct and the indirect
costs of RVAGE in 3 different health care settings (hos-
pital, emergency department, and primary care) [20].
Absenteeism costs were also the highest in every coun-
try surveyed in the REVEAL study, as a consequence of
a variable work loss that ranged from 2.3 days in France
to 7.5 days in the United Kingdom. Other studies with
similar objectives excluded 25% to 80% of the expenses
sources taken into account in these 3 studies [22-25].
Prior to rotavirus vaccine availability in Spain, we per-
formed a study with the same methodology as the cur-
rent study but restricted it to one single centre [18]. We
found that rotavirus cases accounted for 60% of the
total cases and an event of RVAGE was estimated to
cost €427, twice the cost of an episode due to any other
etiology. The differences between our previous study
and the present study may be mainly related to the
implementation of rotavirus vaccine and an actual
decline in the number and severity of RVAGE cases. In
addition, less severe patients have been now included
through the primary care recruiting network.
According to recent epidemiological data regarding
rotavirus disease in Spain, approximately 310,000 cases
of rotavirus-induced diarrhea occur every year in chil-
dren under 5 years of age, causing 14,000 hospitaliza-
tions [16,17,26,27]. Consistent with our study, only the
indirect costs of rotavirus in patients requiring hospital
admission would amount to €3 million every year. A
recently published model of a universal rotavirus vacci-
nation program applied to Spain using cost data consis-
tent with our study, showed that more than 136,000
cases of RVAGE and €60 million (€38 from a societal
perspective) in expenses could be avoided per birth
cohort [27].
The main limitations in our study are those common
to multicentric and economical studies based on the
survey approach. Differences in methodology prevented
direct comparison with some other studies mainly
because of not including/specifying all the sources
detailed in our study. Previous experience of the main
team with the same protocol [18], appropriate training
of the participating subinvestigators and a very conser-
vative approach applied are indicative that the obtained
results are reliable and demonstrative -if not under-esti-
mative- of the actual burden of rotavirus in terms of
indirect costs.
Table 2 Indirect costs
GLOBAL
Mean ± SD (Median)
ROTAVRIUS
Mean ± SD (Median)
OTHERS
Mean ± SD (Median)
p
Job
N° of hours of lost work 19.60 ± 25.36 (10) 28.1 ± 28.9 (20) 15.6 ± 22.9 (8) < 0.001
N° of days of lost work 2.45 ± 3.17 (1,25) 3.5 ± 3.6 (2.5) 1.9 ± 2.9 (1) < 0.001
Costs (€) 91.41 ± 134.76 (40) 120.4 ± 154.1 (72.5) 75.8 ± 123.3 (28.4) 0.002
Travels
N° of Kms. 56.08 ± 113.46 (20) 79.3 ± 158.7 (26.5) 46.7 ± 92.8 (18) 0.050
Costs of travelling (€) 18.66 ± 55.30 (7) 32.1 ± 92.1 (14.8) 12.5 ± 21.1 (5) 0.005
Caregiver (€) 14.70 ± 41.40 (0) 14.8 ± 44.4 (0) 15.7 ± 41.4 (0) 0.873
Meals
N° of meals outside home 5.47 ± 7.46 (2) 8.2 ± 7.8 (6) 4.1 ± 7.1 (1) 0.003
Cost meals (€) 33.33 ± 51.35 (10) 48.5 ± 55.9 (40) 24.3 ± 46.8 (0) < 0.001
Material (€) 34.4 ± 30.7 (27,7) 34.3 ± 25.9 (28.4) 34.0 ± 33.5 (27.0) 0.921
Oral Serum (€) 9.88 ± 9.95 (8,90) 10.2 ± 12.3 (8.5) 9.7 ± 9.03 (8.6) 0.617
Special milk (€) 11.52 ± 21.01 (3,15) 10.2 ± 18.9 (0) 12.6 ± 23.3 (3.3) 0.305
Anti-diarrheal (€) 3.46 ± 5.21 (0) 3.5 ± 5.8 (0) 2.7 ± 4.6 (0) 0.224
Extra diapers (€) 11.89 ± 12.70 (10) 12.3 ± 9.7 (10) 11.2 ± 14.1 (8.5) 0.368
Creams (€) 4.43 ± 6.38 (3) 3.2 ± 4.4 (0) 4.9 ± 7.1 (3) 0.016
Other materials (€) 7.0 ± 12.74 (2,53) 6.01 ± 10.1 (0) 7.8 ± 4.1 (3) 0.197
Other expenses (€) 14.34 ± 92.43 (0) 12.1 ± 39.3 (0) 17.3 ± 19.5 (0.8) 0.711
TOTAL INDIRECT COSTS (€) 135.17 ± 182.70 (67) 192.7 ± 219.8 (99,5) 111.6 ± 163.5 (54,3) < 0.001
“Global” represents all patients included in the study. P values are provided for comparison between rotavirus and other etiologies subgroups.
Bouzón-Alejandro et al. BMC Pediatrics 2011, 11:81
http://www.biomedcentral.com/1471-2431/11/81
Page 4 of 6
Conclusions
In conclusion, rotavirus disease represents a significant
economic burden in terms of indirect costs in our coun-
try. This fact reinforces the interest of rotavirus vaccina-
tion in developed countries and it should be taken into
account in the assessment and decision-making process
of the inclusion of rotavirus vaccine into national immu-
nization programs
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